AI’s use in drug development has generated both excitement and skepticism. While some see it as a game-changer that could speed up the process, others caution that its impact is still uncertain, especially in overcoming high failure rates in clinical trials. Researchers at the University of Michigan are exploring how AI can streamline drug discovery, leveraging their expertise in both pharmaceutical science and machine learning to address these challenges and improve success rates in early-stage development.
